Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02206763
Title Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Gilead Sciences

lung non-small cell carcinoma


Erlotinib + Momelotinib

Age Groups: adult
Covered Countries USA

No variant requirements are available.